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Acquired chromosomal changes are a characteristic of all tumour cells. In 
this chapter we shall briefly review the cytogenetic abnormalities that are 
more specifically associated with acute myeloid leukaemia (AML) and the 
myelodysplastic syndromes (MDS). Their clinical usefulness and their 
significance for the understanding of the mechanism of leukaemogenesis 
will be discussed. 
Mitotic abnormalities had already been discovered in tumour cells by the 
end of the last century (Arnold, 1879). Bovefi (1914) was the first to 
suggest the existence of a relationship between the abnormal chromosome 
pattern and the malignant phenotype of the cells. Nowell and Hungerford 
(1960) reported the constant presence of a small marker chromosome, 
known as the Philadelphia chromosome, in patients with chronic myeloid 
leukaemia (CML). With the use of banding techniques (Caspersson et al, 
1970; Hagemeijer et al, 1979) recurrent patterns of numerical or structural 
chromosome abnormalities were found to correlate with distinct haemato- 
logical malignancies. 
At several International Workshops on Chromosomes in Leukaemia, 
defined correlations were found between cytogenetic abnormalities, 
morphology and immunophenotype, clinical, epidemiological nd aefio- 
logical factors, as well as prognostic implications for therapeutic response 
and survival. The development of molecular genetics in the 1980s led to the 
characterization f the genes involved in the cytogenefic abnormalities. 
These studies revealed a new mechanism of oncogenesis by illegitimate 
gene fusion, as a consequence of translocation. Information was, and still 
is, obtained on the different molecular mechanisms and changes leading to 
malignant transformation. I  addition, these analyses provide insight into 
the genetic control of normal haematopoiesis. 
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CHROMOSOME AND MOLECULAR CHANGES IN AML 
AND MDS 
Cytogenetic findings and clinical significance 
Chromosomal changes can be detected in the majority of cases of acute 
myeloid leukaemia or myelodysplastic syndromes. These changes in karyo- 
type are clonal and an intrinsic feature of leukaemia. With response to treat- 
ment the malignant clone may disappear, but in case of relapse the 
leukaemic ells generally carry the original clonal abnormalities, ome- 
times with additional changes. 
Chromosomal bnormalities can be divided into different categories: 
1. Recurrent structural abnormalities, such as balanced reciprocal 
translocations, inversions and insertions. No gain or loss of chromo- 
some material is found, the conserved breakpoints are specific and have 
often clinical relevance. For instance, adult patients with AML carrying 
the translocation t(8;21), t(15;17) or inversion inv(16) are associated 
with AML FAB M2,M3 and M4eo respectively and known to have a 
better prognosis (Marosi et al, 1992; Swansbury et al, 1994). 
2. Unbalanced aberrations, which include gain or loss of chromosome 
material and, therefore, of genetic material. The breakpoints vary from 
patient to patient. The changes are primary or secondary; they are 
relatively easy to detect and have been associated with various clinical 
entities. 
The distribution of karyotypes may vary among different age groups. In
AML, in children and young adults, there is a predominance of balanced 
translocations (Table la). In the aged or in secondary leukaemia, or MDS 
arising in patients with a history of toxic exposure, there is a predominance 
of numerical and unbalanced abnormalities, in particular a loss or deletion 
of chromosome number 5 (5q-,-5) or #7 (7q-,-7) (Table lb). Trisomy 8, 
in contrast, as a sole or secondary change, is the most frequent abnormality 
in myeloid disorders. Complex karyotypes (more than three aberrations) 
are particularly ominous in all age groups. The specific implications of each 
abnormality for clinical response to therapy will be dealt with below. 
Gene re-arrangements in AML and MDS 
Molecular analysis of a number of recurrent translocations and the inv(16) 
showed involvement of the genes mapping at or very close to the chromo- 
somal breakpoints. Both genes, one on each of the involved chromosomes, 
are interrupted and recombined 'in frame' to give rise to a new hybrid gene. 
The latter is situated on the major or constant recombinant chromosome 
and encodes a new fusion protein. This has been shown to be a major step 
in the chain of events leading to malignancy. Expression of a reciprocal 
product from the second derivative chromosome is sometimes observed. 
These newly formed oncoproteins are expressed in leukaemic ells, and for 
some, their oncogenic potential has been demonstrated in animal studies. A
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ABNORMALITIES IN AML AND MYELODYSPLASTIC SYNDROMES 5 
number of translocations and their fusion transcripts are now defined, and 
several mechanisms by which they might play a role in leukaemic trans- 
formation are suggested (Table 2). 
Table 2. Molecular genetic re-arrangements caused by chromosomal translocations. 
Cytogenetic Involved genes Fusion gene product Putative transforming mechanism 
t(8;21)(q22;q22) ETO (CDR, MTG8); AMLI-ETO (CDR, Suppressor myeloid differentiation 
AML1 MTG8) 
MYH11; CBFB CBFB-MYHll Effects differentiation? 
MYH11; CBFB 
PML; RARA 
inv(l 6)(pl 3;q13) 
t(16;16) 
t(15;17)(q22;q21) 
t(ll;17)(q23;q21) PLZF; RARA 
t(9;11)(p22;q23) AFg; MLL 
t(6;l 1)(p25;q23) AF6; MLL 
t(10;ll)(p12;p23) AFIO; MLL 
t(ll;19)(q23;p13) MLL; ELL 
t(l lq23) MLL; other gene 
t(9;22)(q34;ql 1) ABL; BCR 
t(6;9)(q23;q34) DEK; CAN 
t(16;21)(pll;q22) FUS(TLS); ERG 
t(3;2 l)(q26;q22) EVI-1; AML1 
EAP; AML1 
MDS1; AML1 
t(5;12)(q33;p13) PDGFRB; TEL 
t(3;12)(q26;p13) unknown; TEL 
PML-RARA (100%) Dominant inhibition of 
RARA-PML (70%) promyelocytic differentiation 
PLZF-RARA 
MLL-AF9 
MLL-AF6 
MLL-AF 10 
MLL-ELL 
MLL- other 
BCR-ABL Tyrosine kinase activation 
DEK-CAN 
FUS -ERG 
AML1-EVI-1 Lack of transcriptional activity 
AML1-EAP Repressor gene? 
AML1-MDSI 
TEL-PDGFRB 
Regulator of transcription effect on 
early differentiation 
Originally, gene fusion in AML was thought to be a highly specific 
property of exclusive partners. More recently, genes have been identified 
that may recombine with a variety of other genes; this gives rise to different 
translocations and to leukaemias which can be of different phenotype or 
lineage. For example, the MLL gene on 11q23 and the TEL gene on 12p13 
may be involved in AML, MDS as well as acute lymphoblastic leukaemia 
(ALL). 
Numerical changes and deletions result in gene unbalance. The loss of 
genetic material is suggestive for another mechanism of leukaemogenesis 
by loss of tumour suppression. Such tumour suppressor genes have been 
shown to play a role in familial solid tumours. Many studies currently 
concentrate on the definition of such genes on 5q, 7q, 20q and other 
chromosomal regions that are frequently lost in AML and MDS. 
Methods of detection 
Genetic abnormalities of leukaemic cells can be investigated using a 
number of different techniques: karyotype analysis with banding tech- 
niques, fluorescence in situ hybridization (FISH), Southern blotting, reverse 
transcriptase polymerase chain reaction (RT-PCR) and immunological 
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detection of a specific oncoprotein. The latter two methods assay for the 
RNA and protein product of the oncogene. 
To obtain cells at the metaphase stage, short-term cultures with or with- 
out the use of growth factors or mitogens are applied. Banding techniques 
induce differential staining along the chromosomes, allowing identification 
of each chromosome by microscopy or on photographs. This approach 
reveals a complete picture of the genetic hanges at the chromosomal level, 
i.e. both numerical and structural. It also provides information on the 
complexity of the clonal abnormalities. Sometimes it may also disclose the 
presence of more than one neoplastic ell population. One of the major dis- 
advantages is the limited resolution of banding. On average, achromosome 
band contains from 3 to 5 x 106 DNA base pairs of DNA and may contain 
up to 100 genes. A deletion of part of a band may be submicroscopic and 
therefore not detectable. 
FISH is based on the property of single-stranded DNA to hybridize 
specifically with complementary sequences. DNA probes, specific for a 
chromosome or a given gene, are labelled with non-isotopic haptens uch 
as biotin or digoxigenin (Pinkel et al, 1988). FISH bridges the gap in 
resolution between conventional cytogenetics and molecular DNA tech- 
niques and is becoming more and more sensitive. Larger probes can be used 
on interphase cells, overcoming the necessity to obtain metaphases and 
obviating the possible selection that may occur in culture. Interphase 
molecular cytogenetics allows for the screening of large numbers of cells 
and hence is ideal for follow-up studies of patients and for the detection of 
minimal disease. 
The most interesting feature of FISH is the possibility of combining it 
with other identification techniques like cytomorphology or immunopheno- 
typing (van Lom et al, 1993). Using these approaches, specific genetic 
defects can be assigned to well defined subpopulations of cells and 
reciprocally selective subgroups of cells can be screened for genetic 
changes. 
The chromosomal breakpoints of specific translocations are generally 
clustered in one or a few of the introns of the involved genes. These break- 
point clusters can be probed, and Southern blotting is a major tool for 
diagnosing re-arrangement of those genes--such as the MLL gene--which 
have multiple possible targets. 
The RT-PCR technique amplifies the specific 'fusion transcript' that is 
characteristic of a translocation. RT-PCR, in theory, has the power to detect 
one leukaemic ell among 106 cells, but is also extremely sensitive to 
laboratory contamination. 
The advantage of the molecular analysis is its high sensitivity and 
resolution. The limitation is that only one question at a time can be 
answered. Molecular techniques are used now to evaluate response to 
therapy and measure residual disease in remission samples or forecast 
relapse, or to determine residual eukaemia in autologous haematopoietic 
stem-cell transplants. The same methods are employed to assess donor 
chimerism after allogeneic bone marrow transplantation. They are also very 
convenient to screen particular categories of patient for frequent 
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aberrations with significant prognostic implications (e.g. screening of 
leukaemia for the l lq23 translocation). 
SPECIFIC ABNORMALITIES IN AML 
In this chapter we will deal with the most frequent and clinically most 
significant chromosomal bnormalities. An overview of all translocations, 
the involved genes and their fusion products is given in Tables 1 and 2. 
t(8;21)(q22;q22) 
This is the most frequent ranslocation apparent in about I0% of adult 
patients and 20% of children with AML. It is associated with the AML FAB 
M2, and shows a specific morphology. Typical morphological features of 
t(8;21) AML include eosinophilia, prominent Auer rods, salmon-coloured 
granulae, large cytoplasmic globules and vacuoles. The immunological 
markers CD19 and, less often, CD56, may be present. Loss of a sex 
chromosome may occur, as well as an interstitial deletion of the long arm 
of chromosome 9 del(9)(ql3q32). Both abnormalities are indicative of 
clonal progression. Finally, complex variants of t(8;21) have been 
described. Clinically, AML with t(8;21) is associated with a relatively good 
prognosis with regard to complete remission (80%) and disease-free 
survival (67%) probabilities (Marosi et al, 1992; Dastugue t al, 1995). 
Although relapses do occur in these patients (Feuaux et al, 1989), re- 
induction of remission is often successful, unless secondary abnormalities 
occur (Garson et al, 1989). 
In t(8;21) part of the long arm of chromosome 8 is reciprocally translocated 
to the long arm of chromosome 21. On chromosome 21 the AML1 gene is 
involved (Myoshi et al, 1991), whereas on chromosome 8 it is the ETO gene 
(also called CDR, MTG8). This gene encodes a nuclear protein which 
normally is not expressed in haematopoietic tissue. The translocation results 
in the formation of the AML1-ETO/CDR/MTG8 chimeric fusion gene on the 
derivative chromosome 8, whose transcript can be detected with the use of 
an RT-PCR (Nisson et al, 1992; Erickson et al, 1992; Myoshi et al, 1993). 
AML1 is a highly conserved gene related to the Drosophila pair-role gene 
runt encoding a nuclear protein (Erickson et al, 1992; Daga et al, 1992). 
AML1 is the human counterpart of the murine gene for the alpha subunit of 
the nuclear binding protein (PEPB2) (Bae et al, 1993) also known as the 
core-binding factor (CBF) (Wang and Speck, 1992; Wang et al, 1993). 
PEBP2/CBF is a protein which is able to bind to the enhancers of T-cell 
specific genes and to the conserved core site of the mammalian-type retro- 
viral enhancers. Due to alternative splicing, AML-1 comes in various 
lengths. The normal AMLI gene (full-length form) acts as a transcriptional 
activator reporter gene for CBF, GMCSF CSF1R and TCRB sites 
(reviewed by Nucifora and Rowley, 1995). It is suggested that the shorter 
form of the AML1 gene, AMLla, which still contains the runt domain, can 
act as a suppressor f the reporter gene. Recently, it was found that a larger, 
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alternative spliced form of the AML1 gene, called AMLlb, is capable of 
inducing the transcription of a reporter gene. The t(8;21) fusion protein 
(maintaining the runt homology) appeared to block this transactivation by 
AMLlb (Meyers et al, 1995). This can result in suppression of the normal, 
myeloid differentiation i  cells carrying the t(8;21) (Nuchprayoon et al, 
1991). The breakpoints in the AML1 gene are clustered between exons 5 
and 6 (Myoshi et al, 1991), and result in the formation of a constant size 
fusion transcript regardless of their exact position within the rather large 
intron (de Greef et al, 1995). 
Recently several groups have found that the fusion transcript of AML1- 
ETO persists in patients in long remission (Nucifora et al, 1993a; Kusec et 
al, 1994). This finding would suggest hat the presence of cells with the 
t(8;21) in itself does not indicate the presence of residual leukaemic ells or 
impending relapse, but a quantitative PCR-test should be developed. 
t(3;21)(q26.2;q22) 
The AML1 gene is also known to be involved in t(3;21)(q26;q22). This 
translocation is far less frequent than t(8;21). It is associated not only with 
(therapy-related) AML but also with MDS and blast crisis of CML. On 
chromosome 21 the breakpoints in the AML1 gene are more heterogeneous 
in comparison to t(8;21) and occur after either exon 5 or exon 6 (Sacchi et 
al, 1994). On chromosome 3@6 the EAP gene (Nucifora et al, 1993b), the 
EVI-1 gene (Mitani et al, 1994) and a gene called MDS1 (Nucifora et al, 
1994) have been identified. Chimeric fusions between the AML1 gene and 
the EAP, EVI-1 or MDSI gene have recently been detected by RT-PCR in 
patients with t(3;21) (reviewed by Nucifora and Rowley, 1995). The EAP 
gene is recognized now as the ribosomal protein L.22 and belongs to a 
family of pseudogenes (Toczyski et al, 1993). In a number of patients with 
t(3;21) the chimeric fusion protein AML-1/EAP did not contain amino acid 
homology with normal EAP. Therefore, the transcript might lack its trans- 
activational activity and act as a repressor for the AML1 gene (Nucifora et 
al, 1993b; Sacchi et al, 1994). 
The EVI-I gene can also be found at 3@6 more downstream of the EAP 
and MDS1 genes. It encodes a DNA binding protein and contains two 
domains of zinc finger motifs as well as an acidic domain (Delwel et al, 
1993). The EVI-1 gene is expressed in 30% of patients with AML, MDS or 
CML-blast crisis (CMLBC), without evidence of 3q26 abnormalities 
(Russel et al, 1994). Moreover, it is expressed in leukaemias and MDS 
which carry less frequent 3q26 abnormalities such as t(3;3)(q21;q26) or 
ins(3;3)(q21q25q26). In AML t(3;3)(q21;q26) aswell as inv(3)(q21q26) is 
associated with disturbances in thrombopoiesis and megakaryocyte 
development and is often accompanied by other complex cytogenetic 
abnormalities (Fonatsch et al, 1994). The entire EVI-1 protein is conserved 
in the chimeric transcript resulting from the t(3;21) and expressed in the 
leukaemic ells. Its exact role in the development of leukaemia has not 
been established yet but it might block stem cell differentiation (Matsugi et 
al, 1995). 
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t(15;17)(q22;q21) 
The t(15;17) is clinically associated with acute promyelocytic leukaemia 
(APL), FAB M3, or its microgranular variant M3V, where it is found in 
95% of the cases. This leukaemia is characterized bya clonal expansion f 
haematopoietic progenitor cells, blocked at the promyelocyte stage of 
differentiation (Rowley et al, 1977). Clinically it is associated with 
prominent diffuse intravascular coagulation. APL has a relatively good 
prognosis, and shows theunique property to respond to treatment with 
high-dose all-trans retinoic acid (ATRA), a vitamin A derivative (Huang et 
al, 1988). The reciprocal translocation results in the fusion of the PML gene 
on chromosome 15@2 to the retinoid acid receptor alpha RARA located on 
chromosome 17q21. The fusion product 5'-PML-RARA-3', encoded by the 
der(15), is expressed in all cases. The reciprocal fusion product RARA- 
PML, encoded by the tier(17), is detected in 70% ofAPL. PML is found to 
be expressed in every human cell line, although in human bone marrow it 
is restricted to the myeloid lineage (Daniel et al, 1993). Its expression in 
Hela cells was found to be highest in the G1 phase (Chang et al, 1995). The 
gene has nine coding exons and a proline-rich N-terminus which resembles 
the transcription activation domain of some genes. In addition, three 
clusters of zinc fingers are found followed by an s-helical region. 
Functionally, it has been suggested that the PML gene plays a role as a 
transcription factor (Kakizuka etal, 1991; de The et al, 1991) and is now 
known to belong to a new family of zinc-finger transcription factors, i.e. the 
so-called B-box family (Goddard et al, 1991). Based on the clinical 
response to treatment with ATRA, it has been suggested that disturbances 
of the RARA receptor gene which maps to 17@1 play a role in the patho- 
genesis of APL. A non-functional heterodimer is formed between the PML 
gene and the fusion protein PML-RARA (Perez et al, 1993). Recent data 
show that disturbance ofthe normal function and cellular localization of the 
PML gene product in the presence of PML-RARA affects normal cell 
growth and differentiation (Mu et al, 1994). Also, a positive PML-RARA 
PCR reaction in patients in clinical remission is associated with impending 
relapse (Fukutani et al, 1995). Reports have been made of rare cytogenetic 
variants and masked translocations that involve PML and RARA as well. 
Even more rare are two other translocations a sociated with AML-M3: the 
t(ll;17)(q23;q21) that re-arranges the PLZF gene with RARA (Chen et al, 
1994), and a single report of a t(5;17). So the exact roles of both involved 
genes and their fusion proteins in the pathogenesis ofAPL still remain to 
be established. 
inv(16)(p13q22) and t(16;16)(p13;q22) 
The inv(16)(p13q22) and t(16;16) are also seen at comparatively high 
frequency in de novo AML and account for about 16% of cytogenetic 
abnormalities in these patients. A strong association is apparent between 
chromosome 16 abnormalities and AML FAB M4Eo, but they have also 
been found in AML M2, M4 without eosinophilia, M5, MDS and CML 
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blast crisis (Campbell et al, 1991). Patients usually have a good prognosis 
(almost 100% of CR), but (leptomeningeal) relapses have been reported 
(Holmes et al, 1985). For these reasons, detection of this subtle chromo- 
somal re-arrangement is rather important. Probes for FISH analysis are 
useful to support he diagnosis by conventional cytogenetics. 
On 16p13 the smooth muscle myosin heavy chain gene is involved 
(MYHll) (Liu et al, 1993a; van der Reijden et al, 1993). On 16q22 the 
involved gene has been identified as the core binding factor-[5 gene 
(CBFfl also known as PEPB2/CBF) (Liu et al, 1993b). CBF is known as 
a heterodimeric transcription factor which has DNA binding facilities for 
T-cell and myeloid-specific genes. In addition to the [5 unit, CBF also 
consists of an ~ unit. The latter is coded for by the AML1 gene on 
chromosome 21 and is responsible for DNA interactions. The [5 unit acts 
as stabilizer of this DNA-binding activity. The inv(16) results in an 
abnormal fusion gene 5-'CBFB/MYHll-3'. A single breakpoint has been 
identified within CBFj6, whereas MYHI! may show four alternative 
breakpoints. The fusion product has been identified with the use of RT- 
PCR (Liu et al, 1993a; Claxton et al, 1994). More recently breakpoint 
heterogeneity was demonstrated in both genes (Shurtleff et al, 1995). 
Recent CBF[5-MYHll fusion transcripts were found in a series of AML 
M4Eo, but also in about 10% of AML M4 cases without eosinophilic 
abnormalities (Poirel et al, 1995). Large follow-up series have not yet 
been reported. In analogy to the alternatively spliced AML1-ETO fusion 
transcripts, which may lead to truncated CBFo~ units, alternative splicing 
in the CBF[5 unit has also been identified (van der Reijden et al, 1995). 
In summary both inv(16) and t(8;21) are found in leukaemias with 
relatively good prognosis and both are associated with disturbances 
within the CBF transcription factor. These data may suggest a common 
mechanism of leukaemic transformation. The fusion proteins in combi- 
nation with their alternatively spliced products may exert different effects 
on normal differentiation. 
Abnormalities involving 11q23 
The MLL gene on 11@3, also called HRX, Htrx-1, ALL1 (Djabali et al, 
1992; Gu et al, 1992; Tkachuk et al, 1992; Domer et al, 1993), is involved 
in various chromosomal bnormalities and associated with acute lympho- 
blastic leukaemias (ALL), primary or secondary (therapy-related) AML, 
mixed lineage leukaemia s well as rare cases of myelodysplasia and 
malignant lymphomas. The 11@3 abnormalities are found in more than 
70% of leukaemias in infants (less than 1 year old) but they are also 
relatively frequent in children and adults. As the MLL gene can fuse to a 
number of different partner genes, it plays a role in several chromosomal 
translocations. In ALL, t(4;ll)(q21;q23) is the most frequent 11@3 
abnormality followed by t(ll;19)(q23;p13.3). Patients with ALL and 
t(4; 11) have high WBC, null cell immunophenotype, and are more often of 
the female sex. In children and adults with de novo AML 11@3 abnor- 
malities are found in 4-6% and most frequently involve t(9; 1 l)(p22;q23), 
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t(6; 11 )(q27 ;q23) and t(11; 19)(q23 ;p 13.1 ). An association of 11 q23 abnor- 
malities with FAB M4/M5, high WBC, extramedullary localization, skin 
infiltration, female sex and poor prognosis, has been established in infants 
(Sorensen et al, 1994). In adults with AML M4/M5 the presence of 11q23 
abnormalities may not predict poor prognosis (Bower et al, 1994). In addi- 
tion, other 11 q23 variants, including t(1; 11)(p32;q23), t(X; 11)(q 13;q23), 
t(10;ll)(p12;q23) and t(ll;17)(q23;q25) have been reported in AML. 
Although translocations are most frequently seen, deletions (del 1 lq) have 
also been demonstrated. 1 lq23 abnormalities are also highly prevalent in 
secondary leukaemia in patients previously treated with topoisomerase II 
inhibitors (Gill Super et al, 1993). Many of these translocations exchange 
chromosomal segments of similar size, and they are therefore difficult to 
detect in poorly banded metaphases. The prevalence of MLL re-arrange- 
ment as detected by Southern can be of the order of 10% of the cases. 
The MLL gene on chromosome 11 covers about 100 kb and contains at 
least 21 exons. The MLL protein contains several regions that show 
homology to that of the Drosophila trithorax gene, which is involved in the 
transcriptional regulation in Drosophila embryogenesis. It also contains 
amino-terminal AT hooks which can bind to AT-rich regions of the minor 
groove of the DNA double helix (Grosschedl et al, 1994). In this way it may 
facilitate the action of other DNA-binding factors. The cystein-rich region 
(CRR), also found on the MLL gene product, shows homology with 
mammalian DNA methyltransferase, which might discriminate between 
hemimethylated and ummethylated DNA. All these regions lead to the 
presence of at least two DNA-binding domains (TRX and four zinc-fingers) 
and suggest arole as a transcriptional regulator. The breakpoints in the MLL 
gene are clustered between exons 5 and 1 l of the gene between the two 
DNA-binding sites. At the present time eight different partner genes have 
been molecularly characterized. Some of these share sequence homology, 
such as AFIO (10p12) with AF17 (17q25), and AF9 (9p22) with ENL 
(19p13). However, most do not. Fusion transcripts are found between the 
MLL and its different partner genes, coding for several chimeric proteins 
(for a review see Bernard and Berger (1995)). Although these chimeric 
proteins might influence the normal functions of the MLL gene, the MLL 
fusion protein on the derivative chromosome 11 is expressed in all cases 
and is considered critical in leukaemogenesis (Rowley, 1992; Kobayashi et 
al, 1993; Downing et al, 1994). Several mechanisms of leukaemogenesis of 
MLL might be involved--such as competition for targets of normal MLL or 
formation of a new transcription factor by fusion of AT hooks to possible 
transactivation domains in the product of the partner genes. As a result of 
the differences between most partner genes, they might contribute in 
different ways to leukaemogenesis. The fact that leukaemias carrying 
1 lq23 abnormalities can be of myeloid, lymphoid or mixed lineage, might 
suggest that the critical changes occur in a very early pluripotent progenitor 
cell, and that the different ranslocations interfere with the various path- 
ways of differentiation. 
Another abnormality, also involving the MLL gene, was described in 
AML; in this abnormality an internal tandem duplication took place within 
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the gene. The partially duplicated MLL-1 gene is transcribed into mRNA 
capable of encoding a partially duplicated protein (Schichman et al, 1994). 
This self fusion of the gene has been reported in AML with trisomy 11, but 
also in AML with normal karyotype, and might be considered as another 
mechanism in leukaemogenesis. 
SPECIFIC ABNORMALITIES IN MDS 
The myelodysplastic syndromes harbour a variety of disorders which are of 
clonal origin. They are characterized by ineffective haematopoiesis often in 
combination with hypercellularity of the bone marrow. A classification can 
now be made according to the FAB criteria. The morphological classifi- 
cation already made it possible to define patients which need more 
intensive treatment or even an allogeneic bone marrow transplantation, as 
they have a poor prognosis (for instance, patients with RAEBt). 
In addition to the FAB classification, the chromosomal status can be con- 
sidered as a major prognostic indicator of survival, leukaemic trans- 
formation and response to treatment. Cytogenetic abnormalities are found 
in 32-73% of primary MDS (Second International Workshop on Chromo- 
somes in Leukemia, 1980; Yunis et al, 1988). They consist of numerical 
and/or structural re-arrangements. The most frequent abnormalities found 
are deletion of chromosome 5 (-5/5q-), chromosome 7 (-7/7q-) and 
chromosome 20 (20q-), -Y, or an additional chromosome 8 (+8). Non- 
random translocations are far less frequent (1-5%) and involve chromo- 
somes #3, #6, #9, #16 and #21 in the same way as can be found in patients 
with AML, so they will not be further discussed here. Relations have been 
found between the different FAB classifications and the presence of specific 
chromosomal bnormalities (reviewed by Heim and Mitelman, 1995). For 
instance, del(5q) is found in 50% of MDS type refractory anaemia (RA) 
and in less than 5% in chronic myelo-monocytic leukaemia (CMML). 
Monosomy 7 is less frequent in patients with refractory anaemia with ring 
sideroblasts, (RARS), whereas del(1 lq) and del(20q) are found more often 
in these patients, compared to the other MDS subgroups. In the patients 
with refractory anaemia with excess of blasts (RAEB) or RAEBt, the 
frequency of chromosomal abnormalities increases, which also may be 
more complex (Knapp et al, 1985; Heim and Mitelman, 1986). With respect 
to the prognostic significance of the chromosomal status, various studies 
show different outcome. The chance for leukaemic transformation has been 
found to be smaller in patients with an admixture of normal (N) and abnor- 
mal (A) metaphases in comparison to patients with all abnormal (AA) 
metaphases (Pierre et al, 1989; Gonzalez Manzo et al, 1992). Other studies 
did not confirm this (Yunis et al, 1986; Billstr6m et al, 1988). A recent study 
of 109 patients howed no relation between FAB and specific hromosomal 
abnormalities. Patients with three abnormal cell lines or complex abnor- 
malities had the shortest survival. No statistical difference could be found 
in survival between NN, AN or AA patients (Parlier t al, 1994). Our own 
analysis of 129 patients with primary MDS also showed that overall 
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survival is shortest in the presence of multiple chromosomal bnormalities 
in comparison to single or no chromosomal abnormality (non-published 
data). 
Some specific abnormalities found in MDS are now known to involve 
gene structures which might play a role in the development of the disease. 
For example, mutations of the RAS oncogene and P53 gene have been 
reported in MDS but their exact role remains to be established. 
ABNORMALITIES INVOLVING CHROMOSOME 5 
Deletion 5q 
The interstitial deletion of the long arm of chromosome 5 (5q-) can he 
found in patients with de novo and therapy-related MDS or AML. In the 
latter groups it can be considered as a bad prognostic sign. Within the 5q- 
at least four different interstitial deletions can be identified, spread between 
5q13 and 5q35. Of these, 5q31 is the segment which was found to be 
deleted in most patients (Pedersen and Jensen, 1991). Molecular studies 
have revealed the presence of several genes playing a role in proliferation 
and/or differentiation located on 5q31. These are the interleukin genes 
(IL-3; IL-4; IL-5; IL-9), the genes for GM-CSF; for CSF-1 receptor 
(v-FMS), CD14, the zinc finger transcription factor EGRI and the 
interferon response factor (IRF1). The use of FISH made it possible to 
analyse two distinct critical loci on 5q31 in patients with secondary AML 
and MDS. Both regions called D5S89 and EGR1 were deleted, whereas the 
interstitial region was conserved (reviewed by Nagarajan, 1995). The loss 
of the D5S89 locus involves genes that play a role in myeloid growth and 
differentiation and is found in RAEBt and AML with poor prognosis; it has 
been suggested that D5S89 is the MDS/AML tumour suppressor locus. The 
telomeric region near the CSFR1 gene is considered as regulator of 
erythroid and megakaryocytic differentiation and therefore as RET locus. 
Further studies are essential to isolate all critical genes and to establish the 
consequences of their loss in patients with 5q-. 
t(5;12)(q33;p13) 
The above translocation can be found in Ph-negative CML, chronic myelo- 
proliferative disorders as well as in MDS-CMMOL, although it seems to be 
not very frequent in this group. On the molecular level, the platelet-derived 
growth factor eceptor-B (PDGFRB) gene is involved at 5q33, with the TEL 
gene at 12p13 (Golub et al, 1994). The latter gene is a member of the ETS 
family of transcription factors. In MDS it has also been found in a variant 
t(10;12)(q24;p13) (Wlodarska et al, 1995). Recently it has been found to 
form fusion transcripts also with other genes such as ABL or AML1. In these 
cases often a loss of the other TEL allele occurs leading to a complete loss 
of wild-type TEL in the leukaemic ells. Deletion of TEL is found in 15% 
of children with acute lymphoblastic leukaemia (Stegmaier et al, 1995). 
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SUMMARY 
With the use of molecular techniques it is now possible to define even 
subtle chromosomal abnormalities and the fusion products resulting from 
translocations. Defined clinical correlations can now be made and prog- 
nostic implications are already found. For instance, patients with AML 
carrying t(8;21), t(15;17) or inv(16) have a better prognosis for long-term 
survival. This is also illustrated by Figure 1, which shows data of the Dutch 
HOVON AML study. The definition of patients with a bad or good prog- 
nosis has already resulted in the adjustment of treatment protocols. In the 
near future, with the use of more defined molecular techniques, we might 
be able to characterize the chromosomal abnormality of each patient, to 
individualize his treatment and to recognize very early relapses. 
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Figure 1. Overall survival in relation to cytogenetic abnormalities in 582 adult patients with AML, 
treated according to the HOVON 4(A) protocol. 
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